title: Pellagra: will we see it more frequently?
authors.forename: G
authors.initials: G
authors.lastname: Okan
authors.forename: S
authors.initials: S
authors.lastname: Yaylaci
authors.forename: S
authors.initials: S
authors.lastname: Alzafer
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010383:Pellagra / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D011736:Pyridoxine; D007538:Isoniazid